Dr. Muro on Pembrolizumab for Gastric Cancer

Video

Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment if several types of cancer.

Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment of several types of cancer.

Muro recently presented on the gastric cancer cohort of KEYNOTE-012, which included 39 patients whose tumors expressed PD-L1. The study included 19 Asian and 22 non-Asian patients.

The objective response rate (ORR) was 22.2% and the toxicity profile was very manageable. Median progression-free survival (PFS) was 1.9 months and at 6 months, the PFS rate was 24%, and the overall survival (OS) rate was 69%.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD